WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) said new data from Phase
1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis showed
that, in addition to the strong previously reported efficacy for EASI-related
endpoints, rezpegaldesleukin has the potential to be a differentiated
therapeutic that could greatly improve quality-of-life for patients.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, said: 'We look
forward to advancing rezpegaldesleukin into our robust Phase 2b study in
biologic-naïve patients with moderate to severe atopic dermatitis in October of
this year. We are excited to announce that we are also initiating a Phase 2a
study of rezpegaldesleukin in patients with alopecia areata in early 2024.'

For More Such Health News, visit rttnews.com.



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX